The haNK cell line in combination with avelumab (anti-PD-L1 mAbs) and the cancer vaccine NANT and/or IL-15 is currently undergoing clinical trials in patients with solid malignancies such as relapsed/refractory advanced stage triple negative breast cancer (NCT03387085), squamous cell carcinoma (lung or head and neck) that has progressed after platinum-based chemotherapy and ICI (NCT03387111), and relapsed/refractory pancreatic cancer (NCT03586869). The gene discussed is IL15; the disease is cancer.